Research Divisions, Labs & Researchers
Research at CCII is organized into six divisions, three divisions focused on fundamental research and three divisions focused on clinical and applied research, supported by two focus areas in analytic research, a “Multi-Omics Platform” and an “Informatics Platform”.
Department of Immunology and Genomic Medicine
Our laboratory was the global pioneer in advocating PD-1 antibody-based cancer immunotherapy. Achieving a better understanding of the fundamental biology behind checkpoint inhibitors in human cancer models will help us to build better therapy regimes and enhance the efficiency and effectivity of cancer immunotherapy.
Division of Integrated High-Order Regulatory Systems
Our goal is to build the basic tools for future immune system intervention in cancer and other diseases through research on immune system interactions in health and disease, using advanced proteomics and metabolomics tools.
Division of Cancer Immune Regulation
Division of Cancer Immune Multicellular System Regulation
We are developing unique analytical methods for studying the tumor microenvironment to comprehensively analyze interactions between the immune system and cancer cells. By establishing the concept that genetic abnormalities in cancer cells directly affect immune responses, we are pioneering a new field in tumor biology.
Division of Clinical Immunology and Cancer Immunotherapy
We use immune adverse events in cancer immunotherapy together with bio-makers as model systems to better understand and predict the likelihood of success as well as risk factors of cancer immunotherapy in various types of cancer.
Division of Cancer Immunotherapy
Our goal is to develop next generation cancer immunotherapies that enhance the efficacy of PD-1 blockade. We will maximize immune activation at tumor sites using a two sided approach, i.e. unique innate immunity-activating adjuvant and enhanced tumor destruction.
Division of Clinical Pharmacology and Cancer Immunothearapy
We are at the forefront of pioneering research and development in new molecular targeted therapies and immunotherapies that focus on the vulnerabilities arising from genetic alterations in cancer cells (such as KRAS, TP53, etc.). Our mission is to develop effective and safe treatments tailored to individual patients, with the aim of curing intractable cancers, such as unresectable gastrointestinal cancers.
Multi-Omics Platform
Together with our collaborators at Kyoto University and in industry, we have been building a powerful new multi-omics platform to accelerate research into interactions between cancer and the immune system. This platform is available to all scientists at CCII and Kyoto University.
Infomatics Platform
Our platform advances and supports cancer immunology research by conducting in-silico analysis of quantitative data obtained from various devices, including high-throughput sequencers.
Visiting Researchers
Our goal at CCII is to work closely with organizations in academia and industry in Japan and abroad. Already today, CCII is hosting numerous of scientists from industry or overseas research organizations in visiting positions. CCII’s new research building will provide special facilities for visiting scientists.
Research – At the Forefront of Immunology and Cancer
The history of research on PD-1 goes back to fundamental investigations undertaken three decades ago at Kyoto University. At CCII our goal is to build on these achievements and develop them towards the future.
Working at CCII
Established in April 2020, CCII is devoted to advancing immunology and cancer research. Our goal is to transform society through science.